#BEGIN_DRUGCARD DB01846

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H36N7O17P3S

# Chemical_IUPAC_Name:
{[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-({[hydroxy({hydroxy[(3R)-3-hydroxy-3-[(2-{[2-(hydroxysulfanyl)ethyl]carbamoyl}ethyl)carbamoyl]-2,2-dimethylpropoxy]phosphoryl}oxy)phosphoryl]oxy}methyl)oxolan-3-yl]oxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Oxidized Coenzyme A

# HET_ID:
CAO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H36N7O17P3S/c1-21(2,16(31)19(32)24-4-3-12(29)23-5-6-49-40)8-42-48(38,39)45-47(36,37)41-7-11-15(44-46(33,34)35)14(30)20(43-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-31,40H,3-8H2,1-2H3,(H,23,29)(H,24,32)(H,36,37)(H,38,39)(H2,22,25,26)(H2,33,34,35)/t11-,14+,15-,16-,20+/m0/s1

# InChI_Key:
InChIKey=HWMGJMKHOJKGLQ-VPHNIEJBSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1846

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
783.534

# Molecular_Weight_Mono:
783.110122987

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1T3Z

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.87

# Predicted_LogS:
-2.2

# Predicted_Water_Solubility:
4.91e+00 g/l

# Primary_Accession_No:
DB01846

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936236

# PubChem_Substance_ID:
46506694

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00829

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)(CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:32 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U82167

# Drug_Target_1_GenBank_ID_Protein:
2102704

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
frc

# Drug_Target_1_Gene_Sequence:
>1287 bp
ATGACTAAACCATTAGATGGAATTAATGTGCTTGACTTTACCCACGTCCAGGCAGGTCCT
GCCTGTACACAGATGATGGGTTTCTTGGGCGCAAACGTCATCAAGATTGAAAGACGTGGT
TCCGGAGATATGACTCGTGGATGGCTGCAGGACAAACCAAATGTTGATTCCCTGTATTTC
ACGATGTTCAACTGTAACAAACGTTCGATTGAACTGGACATGAAAACCCCGGAAGGCAAA
GAGCTTCTGGAACAGATGATCAAGAAAGCCGACGTCATGGTCGAAAACTTCGGACCAGGC
GCACTGGACCGTATGGGCTTTACTTGGGAATACATTCAGGAACTGAATCCACGCGTCATT
CTGGCTTCCGTTAAAGGCTATGCAGAAGGCCACGCCAACGAACACCTGAAAGTTTATGAA
AACGTTGCACAGTGTTCCGGCGGTGCTGCAGCTACCACCGGTTTCTGGGATGGTCCTCCA
ACCGTTTCCGGCGCTGCTCTGGGTGACTCCAACTCCGGTATGCACCTGATGATCGGTATT
CTGGCCGCTCTGGAAATGCGTCACAAAACCGGCCGTGGTCAGAAAGTTGCCGTCGCTATG
CAGGACGCTGTTCTGAATCTGGTTCGTATCAAACTGCGTGACCAGCAACGTCTGGAAAGA
ACCGGCATTCTGGCTGAATACCCACAGGCTCAGCCTAACTTTGCCTTCGACAGAGACGGT
AACCCACTGTCCTTCGACAACATCACTTCCGTTCCACGTGGTGGTAACGCAGGTGGCGGC
GGCCAGCCAGGCTGGATGCTGAAATGTAAAGGTTGGGAAACCGATGCGGACTCCTACGTT
TACTTCACCATCGCTGCAAACATGTGGCCACAGATCTGCGACATGATCGACAAGCCAGAA
TGGAAAGACGACCCAGCCTACAACACATTCGAAGGTCGTGTTGACAAGCTGATGGACATC
TTCTCCTTCATCGAAACCAAGTTCGCTGACAAGGACAAATTCGAAGTTACCGAATGGGCT
GCCCAGTACGGCATTCCTTGCGGTCCGGTCATGTCCATGAAAGAACTGGCTCACGATCCT
TCCCTGCAGAAAGTTGGTACCGTCGTTGAAGTTGTCGACGAAATTCGTGGTAACCACCTG
ACCGTTGGCGCACCGTTCAAATTCTCCGGATTCCAGCCGGAAATTACCCGTGCTCCGCTG
TTGGGCGAACATACCGACGAAGTTCTGAAAGAACTGGGTCTTGACGATGCCAAGATCAAG
GAACTGCATGCAAAACAGGTAGTTTGA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
2361939	Baetz AL, Allison MJ: Purification and characterization of formyl-coenzyme A transferase from Oxalobacter formigenes. J Bacteriol. 1990 Jul;172(7):3537-40.
9150242	Sidhu H, Ogden SD, Lung HY, Luttge BG, Baetz AL, Peck AB: DNA sequencing and expression of the formyl coenzyme A transferase gene, frc, from Oxalobacter formigenes. J Bacteriol. 1997 May;179(10):3378-81.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2396

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
47328

# Drug_Target_1_Name:
Formyl-coenzyme A transferase

# Drug_Target_1_Number_of_Residues:
428

# Drug_Target_1_PDB_ID:
1P5R

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02515	CoA_transf_3

# Drug_Target_1_Protein_Sequence:
>Formyl-coenzyme A transferase
MTKPLDGINVLDFTHVQAGPACTQMMGFLGANVIKIERRGSGDMTRGWLQDKPNVDSLYF
TMFNCNKRSIELDMKTPEGKELLEQMIKKADVMVENFGPGALDRMGFTWEYIQELNPRVI
LASVKGYAEGHANEHLKVYENVAQCSGGAAATTGFWDGPPTVSGAALGDSNSGMHLMIGI
LAALEMRHKTGRGQKVAVAMQDAVLNLVRIKLRDQQRLERTGILAEYPQAQPNFAFDRDG
NPLSFDNITSVPRGGNAGGGGQPGWMLKCKGWETDADSYVYFTIAANMWPQICDMIDKPE
WKDDPAYNTFEGRVDKLMDIFSFIETKFADKDKFEVTEWAAQYGIPCGPVMSMKELAHDP
SLQKVGTVVEVVDEIRGNHLTVGAPFKFSGFQPEITRAPLLGEHTDEVLKELGLDDAKIK
ELHAKQVV

# Drug_Target_1_Reaction:
formyl-CoA + oxalate = formate + oxalyl-CoA

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the transfer of the CoA moiety from formyl-CoA to oxalate. Essential enzyme for the bacterium survival, as it relies on oxalic acid as its sole source of energy

# Drug_Target_1_SwissProt_ID:
O06644

# Drug_Target_1_SwissProt_Name:
FCTA_OXAFO

# Drug_Target_1_Synonyms:
EC 2.8.3.16
Formyl-CoA transferase

# Drug_Target_1_Theoretical_pI:
5.10

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X12455

# Drug_Target_2_GenBank_ID_Protein:
580740

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>1917 bp
GTGAGCGAAATCATCCGCGTACCCGATATCGGCGGCGATGGGGAAGTCATCGAATTGCTG
GTCAAGACCGGCGACCTCATCGAGGTCGAGCAGGGGCTGGTGGTGCTGGAGTCCGCCAAG
GCGAGCATGGAAGTTCCCAGTCCCAAGGCCGGAGTGGTCAAGAGCGTGAGCGTCAAGCTG
GGCGACAAGCTCAAGGAAGGCGACGCGATCATCGAGCTGGAACCTGCCGCCGGTGCCGCG
GCGGCACCTGCCGAAGCGGCGGCCGTGCCCGCCGCGCCGACCCAGGCCGTCGACGAGGCC
GAGGCGCCCTCTCCCGGCGCCTCCGCCACGCCCGCGCCGGCCGCCGCCAGCCAGGAGGTC
CGGGTTCCCGACATCGGCTCGGCCGGCAAGGCACGGGTCATCGAGGTGCTGGTCAAGGCC
GGCGACCAGGTCCAGGCCGAGCAGTCGCTGATCGTGCTGGAGTCCGACAAGGCCAGCATG
GAGATCCCCTCCCCGGCTTCCGGAGTGGTGGAAAGCGTCGCCATCCAGTTGAACGCCGAG
GTCGGCACCGGCGACCTGATCCTCACCCTGCGCACCACCGGCGCCCAGGCCCAGCCTACG
GCGCCCGCCGCGGCCGCGGCCGCGAGCCCGGCACCCGCTCCGCTGGCTCCGGCCGCCGCC
GGTCCCCAGGAAGTCAAGGTCCCGGACATCGGCTCGGCCGGCAAGGCACGGGTCATCGAG
GTGCTGGTCAAGGCCGGCGACCAGGTCCAGGCCGAACAGTCGCTGATCGTGCTGGAATCC
GACAAGGCCAGCATGGAGATCCCCTCCCCGGCCGCCGGGGTGGTGGAAAGCGTCGCCGTC
CAGTTGAACGCCGAGGTCGGCACCGGCGATCAGATCCTCACCCTGCGCGTCGCCGGCGCC
GCGCCGAGCGGCCCCCGCGCCCGCGGCAGCCCCGGCCAAGCCGCCGCCGCTGCGGCCGCT
GCCCCGGCTCCGGCCCCGGTCGGCGCACCGAGCCGCAACGGCGCCAAGGTGCATGCCGGC
CCCGCCGTGCGCCAACTGGCCCGCGAGTTCGGCGTCGAACTGGCGGCGATCAACAGCACC
GGTCCGCGCGGGCGCATCCTCAAGGAGGACGTGCAGGCCTACGTCAAGGCGATGATGCAG
AAGGCCAAGGAGGCGCCGGCCGCCGGCGCGGCCAGCGGCGCCGGCATCCCGCCGATTCCG
CCGGTCGACTTCGCCAAGTACGGCGAAATCGAAGAAGTGCCGATGACTCGCCTGATGCAG
ATCGGCGCGACCAACCTGCACCGCAGTTGGCTGAACGTGCCGCACGTGACCCAGTTCGAG
TCGGCCGATATCACCGAGCTGGAAGCCTTCCGCGTCGCGCAGAAGGCCGTCGCCGAGAAG
GCCGGGGTCAAGCTGACCGTGCTGCCGCTGCTGCTCAAGGCCTGCGCCTACCTGCTCAAG
GAGCTGCCGGACTTCAACAGCTCCCTGGCACCCAGCGGCCAGGCGCTGATCCGCAAGAAG
TACGTGCACATCGGCTTCGCCGTGGACACCCCGGACGGCCTGCTGGTGCCGGTAATCCGC
AACGTCGACCAGAAGAGCCTGCTGCAACTGGCCGCCGAGGCCGCCGAACTGGCGGAGAAG
GCGCGCAGCAAGAAGCTCGGCGCCGACGCCATGCAGGGTGCCTGCTTCACCATCTCCAGC
CTCGGCCACATCGGCGGCACGGCCTTCACGCCGATCGTCAACGCCCCGGAAGTGGCGATC
CTCGGCGTGTCCAAGGCCAGCATGCAGCCGGTATGGGACGGCAAGGCCTTCCAGCCGCGC
CTGATGCTGCCGCTGTCGCTGTCCTACGATCACCGGGTGATCAACGGCGCCGCCGCGGCG
CGCTTCACCAAGCGTCTCGGCGACCTGCTGGCGGATATCCGCGCCATCCTGCTGTGA

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
1549782	Mattevi A, Obmolova G, Schulze E, Kalk KH, Westphal AH, de Kok A, Hol WG: Atomic structure of the cubic core of the pyruvate dehydrogenase multienzyme complex. Science. 1992 Mar 20;255(5051):1544-50.
3191993	Hanemaaijer R, Vervoort J, Westphal AH, de Kok A, Veeger C: Mobile sequences in the pyruvate dehydrogenase complex, the E2 component, the catalytic domain and the 2-oxoglutarate dehydrogenase complex of Azotobacter vinelandii, as detected by 600 MHz 1H-NMR spectroscopy. FEBS Lett. 1988 Nov 21;240(1-2):205-10.
3292237	Hanemaaijer R, Janssen A, de Kok A, Veeger C: The dihydrolipoyltransacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. Molecular cloning and sequence analysis. Eur J Biochem. 1988 Jul 1;174(4):593-9.
3691494	Hanemaaijer R, de Kok A, Jolles J, Veeger C: The domain structure of the dihydrolipoyl transacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. Eur J Biochem. 1987 Dec 1;169(2):245-52.
8068086	Berg A, de Kok A, Vervoort J: Sequential 1H and 15N nuclear magnetic resonance assignments and secondary structure of the N-terminal lipoyl domain of the dihydrolipoyl transacetylase component of the pyruvate dehydrogenase complex from Azotobacter vinelandii. Eur J Biochem. 1994 Apr 1;221(1):87-100.
9119000	Berg A, Vervoort J, de Kok A: Three-dimensional structure in solution of the N-terminal lipoyl domain of the pyruvate dehydrogenase complex from Azotobacter vinelandii. Eur J Biochem. 1997 Mar 1;244(2):352-60.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2377

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
65045

# Drug_Target_2_Name:
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex

# Drug_Target_2_Number_of_Residues:
638

# Drug_Target_2_PDB_ID:
1DPD

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00198	2-oxoacid_dh
PF00364	Biotin_lipoyl
PF02817	E3_binding

# Drug_Target_2_Protein_Sequence:
>Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex
MSEIIRVPDIGGDGEVIELLVKTGDLIEVEQGLVVLESAKASMEVPSPKAGVVKSVSVKL
GDKLKEGDAIIELEPAAGAAAAPAEAAAVPAAPTQAVDEAEAPSPGASATPAPAAASQEV
RVPDIGSAGKARVIEVLVKAGDQVQAEQSLIVLESDKASMEIPSPASGVVESVAIQLNAE
VGTGDLILTLRTTGAQAQPTAPAAAAAASPAPAPLAPAAAGPQEVKVPDIGSAGKARVIE
VLVKAGDQVQAEQSLIVLESDKASMEIPSPAAGVVESVAVQLNAEVGTGDQILTLRVAGA
APSGPRARGSPGQAAAAPGAAPAPAPVGAPSRNGAKVHAGPAVRQLAREFGVELAAINST
GPRGRILKEDVQAYVKAMMQKAKEAPAAGAASGAGIPPIPPVDFAKYGEIEEVPMTRLMQ
IGATNLHRSWLNVPHVTQFESADITELEAFRVAQKAVAEKAGVKLTVLPLLLKACAYLLK
ELPDFNSSLAPSGQALIRKKYVHIGFAVDTPDGLLVPVIRNVDQKSLLQLAAEAAELAEK
ARSKKLGADAMQGACFTISSLGHIGGTAFTPIVNAPEVAILGVSKASMQPVWDGKAFQPR
LMLPLSLSYDHRVINGAAAARFTKRLGDLLADIRAILL

# Drug_Target_2_Reaction:
acetyl-CoA + enzyme N6-(dihydrolipoyl)lysine = CoA + enzyme N6-(S-acetyldihydrolipoyl)lysine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_2_SwissProt_ID:
P10802

# Drug_Target_2_SwissProt_Name:
ODP2_AZOVI

# Drug_Target_2_Synonyms:
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex
E2
EC 2.3.1.12

# Drug_Target_2_Theoretical_pI:
5.12

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01846
